Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects
Open Access
- 1 August 2015
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (8) , 1703-1712
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factorXa inhibitor, in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Apixaban in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementNew England Journal of Medicine, 2010
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialThe Lancet, 2010
- Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and HumansDrug Metabolism and Disposition, 2009
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to HumansDrug Metabolism and Disposition, 2009
- Biopharmaceutics Classification System: The Scientific Basis for Biowaiver ExtensionsPharmaceutical Research, 2002